Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Zybio
Chongqing, Chongqing, Chinazybio.com ↗
- Ownership
- Private
- Employees
- ~700
- Development stage
- Commercial
01
Overview
Zybio has commercialized a broad portfolio of in vitro diagnostic products including automated nucleic acid isolation systems and reagents for molecular diagnostics. Their SARS-CoV‑2 antigen assay kits are approved for self-testing use. The company also offers mass spectrometry solutions for microbial laboratories.
- Therapeutic areas
- Infectious Diseases
- Modalities
- DeviceDiagnostic reagentMolecular diagnostic kitImmunoassay reagentChemistry analyzer/reagentHematology analyzer/reagentPoint-of-care testing (POCT) device/reagentBiomaterial reagent/device
- Industry
- Molecular Diagnostics
02
Partnerships
Cambridge BioscienceGlobal academic collaborations with experts in clinical diagnosis
Beyond the preview
Go deeper on Zybio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zybio.